Open AccessImpact of baseline characteristics on extensive‐stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study
Author(s) -
AbdelRahman Omar
Publication year - 2018
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12950
Subject(s) - medicine , univariate analysis , multivariate analysis , oncology , carboplatin , proportional hazards model , etoposide , performance status , univariate , stage (stratigraphy) , multivariate statistics , chemotherapy , cisplatin , paleontology , statistics , mathematics , biology
Abstract Background The purpose of the current study is to investigate the impact of baseline characteristics on the outcomes of extensive‐stage small cell lung cancer (SCLC) patients recruited into a clinical trial. Methods This is a secondary analysis of the control arm (etoposide/carboplatin arm) of the ‘NCT00363415’ study which is a phase III study conducted between 2006 and 2007. Univariate analysis of factors affecting overall and progression‐free survival (PFS) was conducted through Cox regression analysis [including age, race, gender, Eastern Cooperative Oncology Group performance score, body mass index, Lactate dehydrogenase, number of metastatic sites and brain metastases]. Factors with P < .05 in the univariate analysis were then included in the multivariate analysis. Results All patients within the control arm (etoposide/carboplatin) were included in the analysis (N = 455 patients). The following factors were predictive of worse overall survival (OS) in univariate analysis ( P < .05): performance score = 2, LDH > upper limit of normal and ≥3 metastatic sites. Multivariate Cox regression analysis incorporating these three factors showed that only number of metastatic sites predicts worse OS ( P < .0001) . Likewise, the following factors were associated with worse PFS in univariate analysis ( P < .05): performance score = 2 and ≥ 3 metastatic sites predict worse PFS ( P < .05). Multivariate analysis incorporating these two factors showed that only number of metastatic sites predicts worse PFS ( P < .0001). Conclusion Number of metastatic sites is the most important predictive factor for overall and PFS among patients with extensive‐stage SCLC treated with systemic chemotherapy within a clinical trial.